Paragon Gene Therapy, part of Catalent Biologics, will provide materials for preclinical and Phase 1/2 trials for IVERIC’s gene therapy product candidates
Voyager gains worldwide rights to VY-HTT01 Huntington’s disease program and ex-U.S. rights to VY-FXN01 Friedreich’s ataxia program for $10 million upfront
For the development of a collection of tumor explant models from patients who developed acquired resistance to targeted therapies following initial responses
New drug product manufacturing facility in Waigaoqiao Free Trade Zone of Shanghai has passed its first GMP inspection by the European Medical Products Agency
R&D partnership involves the LRRK2 kinase inhibitors derived from Oncodesign's proprietary Nanocyclix platform, and their potential to act against Parkinson's